Fidelta’s Capabilities In Antiviral Drug Discovery

The scientists at Fidelta are continuously developing innovative approaches, in vitro assays and in vivo models to support cutting-edge research in drug discovery in an effort to better understand mechanisms of infection, host-pathogen interactions, inflammation and fibrosis with the overreaching goal to progress promising new compounds to the clinic.

The in vitro pharmacology team at Fidelta recently developed a cell-based assay for testing of novel compounds against human corona viruses in BSL2 environment that can significantly speed up the process of compound testing prior to assessing their effectiveness against SARS-CoV-2. This in vitro corona virus testing platform (presented this May at the ATS 2021 International Conference) has already proven to be a useful tool in SARS-CoV-2 research in a collaborative effort to identify promising small molecules for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses – led by Sosei Heptares.

Using this approach, combined with the expertise of our in vivo pharmacology team and in-house established animal models with a variety of different read outs, we are capable of screening compounds for their efficacy against corona viruses in BSL2 conditions in vitro and test the efficacy of novel compounds in amelioration and treatment of long-lasting post COVID-19 effects in vivo.

Double IF on lung tissue (target/CD206)

We are, therefore, well-placed to provide our support to current and future antiviral drug discovery activities using our capabilities and experience in drug discovery research.

Contact us at: sales@fidelta.eu and sales@selvita.com